39 results about "Vascular problem" patented technology

The present invention provides methods for treating vascular diseases with hemogenic endothelial cells (HEs) obtained in vitro from pluripotent stem cells. The present invention also provides compositions and methods of producing the HEs.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The present disclosure is directed to compositions comprising between 50% and 95% weight per weight (w / w) of acetic acid, between 0.1% and 5% (w / w) of butyric acid or a derivative thereof, and between 0.1% and 5% (w / w) of Quercetin or a derivative thereof. Further, methods of use such as for the treatment and prevention of a medical condition associated with cancer, inflammatory diseases or disorders, metabolic disorders, obesity, diabetes, high blood pressure, vascular diseases, viral infection, and any combination thereof, in a subject in need thereof are also provided.

The application discloses a portable detection kit for assisting in predicting a cerebral vascular risk, a blood sample is processed through a sample processing module and input corresponding test paper, a detection result of the test paper is collected by a biological sensing module, and the detection result is calibrated and temporarily stored through an electronic control module, so that a user can acquire the calibrated detection result through a target device in an NFC touch mode and automatically send the calibrated detection result to a cerebral vascular disease monitoring digital platform, cerebral vascular risk prediction is performed by the cerebral vascular disease monitoring digital platform, and the portable detection kit has the beneficial effects of high portability, simple operation and high detection result accuracy.

This invention discloses an intestinal fungus Saccharomyces cerevisiae M7015 and its applications belong to the field of microbial technology. Saccharomyces cerevisiae The accession number for M7015 is GDMCC No. 66195. This invention first demonstrated, using a mouse subcutaneous stroma embolism model, that the aforementioned strain can promote angiogenesis; secondly, using mouse and Bama miniature pig myocardial infarction models, it was found that the aforementioned strain can promote collateral angiogenesis in ischemic areas of the heart and improve cardiac function. This invention not only fully elucidates... Saccharomyces cerevisiae M7015 promotes the formation of collateral vessels in the heart and improves cardiac function, and also reveals the broad application prospects of this bacterium in the treatment of vascular diseases.

The present invention discloses the use of a compound of formula I sertaconazole or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for preventing or treating oxidative stress-related cardiovascular diseases. Specifically, the present invention relates to the use of said compound in the preparation of a medicament for preventing or treating oxidative stress-related vascular diseases, including but not limited to acute coronary syndrome, alcoholic heart dysfunction, hypoxic pulmonary arterial hypertension, heart failure, drug-induced cardiotoxicity and stroke, especially acute heart failure.

The present disclosure relates to methods and systems for quantifying the vascular pattern using ocular imaging that shows vessel profiles for the detection, prevention, and treatment of diabetic retinopathy and other related ocular vascular diseases.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

Described herein are compounds of Formula I,wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or peripheral vascular disease.

This disclosure relates to methods of treating or preventing aneurysms or other vascular diseases of conditions related thereto comprising administering an effective amount of a hydroimidazopyridopyrimidinone derivative or salt thereof to a subject in need thereof. In certain embodiments, the derivative comprises a 2,4,6,7,8,9-hexahydro imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5 (1H)-one core structure comprising substituents. In certain embodiments, the compound is 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexa-hydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one (ONC201 / TIC10), derivative, or salt thereof.

This invention relates to the field of neural network construction technology, and more particularly to a method and system for constructing a dynamic prediction model for cerebrovascular diseases based on artificial intelligence. The invention first constructs a graph network model with continuous time slices and defines multimodal feature nodes. Based on the evolutionary correlation of historical data, pruning and sparsity constraints are applied to the fully connected matrix between layers to construct a sparse topology model. Subsequently, fact evolution nodes are activated based on patient clinical data, and reverse path backtracking is performed with these nodes as endpoints. A masking mechanism is used to block non-predetermined fact branches, locking the unique historical path. Finally, this path is transformed into a context vector and injected into subsequent layers to achieve model state reconstruction and dynamic weight updates. This invention, through a global pruning-path locking-dynamic reconstruction mechanism, effectively filters clinical noise in disease progression, solves the path drift problem of traditional time-series prediction, and significantly improves the accuracy of individualized predictions in the mid-to-late stages while greatly reducing the number of parameters.

Providing quinazolindione compounds and their uses. [Solution] Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The present application relates to the application of phospholipids in regulating angiogenesis, and the present application applies various phospholipids and products thereof to a zebrafish model to evaluate the influence of the phospholipids on the damage of intersegmental vessels (ISVs) induced by vascular endothelial cell growth factor receptor inhibitor (PTK787) and the growth of subintestinal vessels (SIVs) in the zebrafish, and it is found for the first time that phospholipids from different sources and in different forms can reverse the damage of ISVs induced by PTK787, significantly promote the growth of SIVs in the zebrafish, and increase the length of the generated blood vessels to different degrees, and have small toxic and side effects; the present application can provide candidates for preparing drugs for vascular diseases, and has a good application prospect.

The application relates to the technical field of cerebral vascular disease prediction, in particular to a large arteriosclerotic cerebral stroke risk prediction method and system. The application can effectively evaluate the risk of cerebral vascular disease, especially cerebral stroke, by combining multiple indexes and image group characteristic data, can obtain score data reflecting the risk development state of the current cerebral stroke, and can more intuitively determine the wind direction degree through the score data, so that the overall automatic prediction of cerebral stroke is realized.

The application provides a lower limb peripheral vascular disease adjustable splint nursing device, and belongs to the technical field of medical devices. The lower limb peripheral vascular disease adjustable splint nursing device comprises two fixed plates, a plurality of air bags are fixedly installed on the inner wall of the fixed plate, a notch is formed in the position corresponding to the air bag on the inner wall of the fixed plate, an adjusting assembly is installed inside the notch, the adjusting assembly is used for adjusting the pressure of the air bag on the patient's limbs, a plurality of pressure adjusting assemblies are installed on the side wall of the fixed plate, the pressure adjusting assemblies are used for reducing the pressure in the air bag when the patient walks and exerts force on the legs, the pressure adjusting assembly comprises a piston cylinder, a driving assembly is installed at the lower end of the fixed plate. In the above scheme, the pressure adjusting assembly cooperates with the driving assembly to dynamically adjust the pressure of the air bag on the patient's legs when the patient walks, so that the overlarge pressure of the air bag on the patient's legs caused by the swelling of the leg muscles during walking is avoided, the therapeutic effect is ensured, and the use experience of the patient is improved.

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing diseases (e.g., proliferative diseases (e.g., cancers and benign neoplasms), inflammatory diseases (e.g., rheumatoid arthritis), and vascular diseases (e.g., atherosclerosis) in a subject. Provided are methods of inhibiting a INK (e.g., JNK1, JNK2, or JNK3) in a subject.

Disclosed herein are aminocarboxymuconate-semialdehyde decarboxylase (ACMSD) inhibitors, pharmaceutical compositions, and methods of using these compounds to treat or prevent one or more ACMSD-related diseases, such as a muscle structural disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass abnormality disorder, a beta-oxidation disease, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, an ocular muscle disease, a liver disease, an inflammatory disease, or a kidney disease.

A perfusion angiography for peripheral vascular disease assessment in combination with photoplethysmographic imaging. An apparatus (13) and method for performing perfusion imaging receives image sequences concurrently acquired by an X-ray imaging device (2) and by a photoplethysmographic imaging device (3). When temporally aligned, the perfusion status of perfused organ tissue is extracted from both image sequences over time and images are generated for display on a display unit (5) that indicate changes in perfusion status at various locations of the perfused organ tissue, thereby capturing both deep and superficial organ tissue perfusion properties. A reduction in image signal intensity in the photoplethysmographic images caused by a bolus of previously administered contrast agent (10) passing through can be used to temporally align the two concurrently acquired image sequences.

The application provides medical uses of knocking down or inhibiting a circular RNA circ0030586, in particular, applications of a substance for knocking out or knocking down circ0030586 or a substance for inhibiting expression of circ0030586 in (A1)-(A2) as follows: (A1) preparing a drug for treating or assisting in treating a cardiovascular disease caused by endothelial dysfunction; (A2) preparing a drug for preventing or assisting in preventing a cardiovascular disease caused by endothelial dysfunction. In patients with atherosclerosis caused by endothelial dysfunction and cell and animal models related to atherosclerosis, it is found that inhibiting circ0030586 can delay the progression of atherosclerosis; the application provides a new target for diagnosis and treatment of atherosclerosis related vascular diseases caused by aging, and opens up a new direction for preparation of prevention and treatment drugs.

Devices and methods for exploiting intramural (e.g., subintimal) space of a vascular wall to facilitate the treatment of vascular disease, particularly total occlusions. For example, the devices and methods disclosed herein may be used to visually define the vessel wall boundary, protect the vessel wall boundary from perforation, bypass an occlusion, and / or remove an occlusion.

The application provides a cerebral vascular disease risk assessment method and device based on a large model intelligent agent, the method comprising: acquiring multi-source information of a user, the multi-source information of the user representing a comprehensive health status of the user; according to the multi-source user information, combining a cerebral vascular disease knowledge base, acquiring corresponding medical guideline knowledge fragments as context reference materials; inputting the multi-source user information and the context reference materials into a health status assessment model to obtain a health status assessment result output by the health status assessment model, the health status assessment result comprising a cerebral vascular disease risk assessment result and health guidance suggestions; through the multi-source user information and the introduction of the cerebral vascular disease knowledge base, the model can simultaneously consider multiple factors such as physiological indicators, medical history backgrounds and lifestyles of the user, and combined with the implied medical logic, the evaluation process is ensured to have a basis, the professional degree and the reliability of the evaluation result are significantly improved, and the personalized generation of the suggestion content is realized.

In particular, compositions comprising iPSC-derived parietal cell precursors (iMPCs) generated using NK3 homeobox 1 (NKX3.1; parietal cell fate-determining transcription factor) and methods for their preparation and use are described herein. In addition, in particular, methods for maturing iMPCs into functional parietal cell subtypes, including smooth muscle cells, perivascular cells, and fibroblasts, as well as methods for increasing angiogenesis, angiogenesis, and cell junctions, are described herein. iMPCs mediate the formation of functional blood vessels when transplanted together with endothelial cells (ECs); thus, methods for modeling vascular diseases (e.g., 3D vascular organoids (VOs)) and therapeutic vascularization, comprising a method of administering iMPCs and ECs and a step of administering iMPCs and ECs, are also described herein.

The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and / or tumors more generally. Therapeutic and / or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.

To provide effective therapeutic agents for the treatment of refractory lymphatic and vascular diseases. Provided is a therapeutic agent for the treatment of refractory lymphatic and vascular diseases which contains sirolimus as an active ingredient. The administration of the therapeutic agent is initiated by oral or tube administration at a dosage determined according to parameters related to the pharmacokinetics of sirolimus in a patient having the disease and the weight and age of the patient.

The application discloses an intelligent wrist watch integrated with multi-modal health monitoring and weak laser treatment functions and a control method thereof, and belongs to the technical field of class II medical devices. The wrist watch realizes continuous monitoring of nine physiological parameters through a wrist multi-sensor fusion architecture, calculates ICSR (ischemic cardio-cerebral vascular risk) scores by using a time sequence fusion network based on LSTM-Attention, and establishes a quantitative mapping relationship between the scores and laser parameters of three wavelengths of 650nm / 830nm / 940nm. The application first synchronizes laser pulse output with cardiovascular hemodynamics cycle accurately: the R wave of an ECG signal is used to identify the ventricular ejection starting moment, and a 650nm pulse (pulse width 80ms) is triggered after a delay of 50ms; the rising edge of a PPG signal is used to identify the microcirculation blood flow acceleration starting moment, and an 830nm pulse (pulse width 40ms) is triggered after a delay of 100ms; a 940nm continuous wave covers the complete cardiac cycle. An exponential decay sliding window mechanism is used to realize 24-hour energy accumulation safety control (threshold 50J / cm²), and a comparator-AND gate hardware circuit is used to forcibly cut off the laser drive. A double-battery physical isolation architecture ensures continuous operation of vital sign monitoring when the laser fails, and meets the IEC 60601-1 standard. The application is suitable for the auxiliary treatment and daily risk management of ischemic cardio-cerebral vascular diseases and hyper-viscosity.

The application provides an auxiliary device for treating peripheral vascular diseases, relates to the technical field of nursing apparatuses, and comprises a massage pad, a hydraulic locking pitching mechanism, a hydraulic driving lifting mechanism and a remote control mechanism, the massage pad is arranged on the pitching mechanism, the pitching mechanism is arranged on the lifting mechanism, the remote control mechanism comprises a hand pump and a locking oil cylinder, the hand pump is linked with the lifting mechanism, and the locking oil cylinder is linked with the pitching mechanism.In the application, the hand pump is used for driving the lifting mechanism to lift, and the locking oil cylinder is used for locking the pitching mechanism, so that the remote adjustment effect is realized, the patient can use the device by himself, and the device does not need external power supply, and is more flexible in use.

The application relates to a balloon catheter. The balloon catheter comprises a balloon, a tube body, a guide wire tube, a plurality of stress concentration elements and at least one stress adjusting film; the tube body is connected with one end of the balloon, a liquid delivery channel is formed in the tube body, the liquid delivery channel is communicated with the balloon, a liquid inlet is arranged at the end of the tube body far from the balloon, and the liquid inlet is communicated with the liquid delivery channel; one end of the guide wire tube is connected with the end of the balloon far from the tube body, the balloon is sleeved outside the guide wire tube, and the guide wire tube passes through the balloon and the tube body; the plurality of stress concentration elements are arranged on the outer surface of the balloon; and the stress adjusting film partially covers or fully covers at least one stress concentration element. According to the scheme, when the balloon is expanded, the stress adjusting film is deformed under pressure, and a more smooth treatment protrusion with a specific treatment profile is formed outside the stress concentration element. The structure can not only effectively act on vascular diseases, but also can disperse the stress borne by the stress concentration element.

In various designs, a device for the treatment of vascular disease includes a stent graft (100) with an external surface and at least two side-branching portals (110), each with a proximal and a distal end. Each distal end is virtually contiguous to the external surface of the stent graft. In other designs, the distal ends are usually more axially separated than the proximal ends.

The application discloses an application of an agonist of a cAMP-activated exchange protein in preparation of a drug for treating preeclampsia, and belongs to the technical field of biological medicines, wherein the drug is used for treating preeclampsia by activating a Rap1 signal pathway of human aortic smooth muscle cells inhibited by a RASA3 protein, and the agonist of the cAMP-activated exchange protein is 8-CPT-2'-O-Me-cAMP or a pharmaceutically acceptable salt or solvent mixture thereof. The application proves for the first time that the compound has a function of promoting migration and remodeling in vascular smooth muscle cells, and successfully applies the compound to the treatment of preeclampsia, a pregnancy-related vascular disease, thereby expanding a new use of the compound in the field of clinical treatment of preeclampsia.